AVAX Technologies' O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer

Data presented at the annual meeting of the American Society of Clinical Oncology

Kansas City, MO, May 22, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) (May 20-23) in New Orleans on the company's autologous cell vaccine (AC Vaccine™) O-Vax™, for ovarian cancer. The data gathered from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer extend earlier findings indicating that O-Vax induces a positive immunological and clinical response in ovarian cancer patients who are refractory to conventional chemotherapy. The presentation, entitled "Immunological and clinical effects of autologous, hapten-modified vaccine in patients with advanced ovarian carcinoma," offers data based on studies conducted by David Berd, M.D., Professor of Medicine, and Charles Dunton, M.D., Professor of Obstetrics and Gynecology, Thomas Jefferson University.

The extended data reflect the follow-up of 10 ovarian cancer patients with metastatic ovarian carcinoma whose tumors had progressed after failing to respond to both first and second-line chemotherapy. They were treated with seven weekly intradermal injections of O-Vax. Despite their large tumor burdens and prior chemotherapy, 8 out of 10 patients responded favorably to the vaccine, as measured by a delayed type hypersensitivity test (DTH), a skin test that measures the patient's immune response against that patient's own unmodified tumor cells. Favorable clinical responses were also observed: one patient exhibited complete regression of an abdominal mass as evidenced by a CT scan and a concomitant normalization of the CA-125 level, a protein found in the blood, which is useful for detecting and evaluating ovarian cancer. In 3 other patients, there was a transient (1-3 months duration) fall in CA-125 without radiological evidence of tumor regression. Seven o

Contact: Sue Yeoh
201-641-2408 ext. 43
AVAX Technologies, Inc.

Page: 1 2 3

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies AC Vaccine™ improves relapse-free survival
4. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: